Director Vincent Milano Buys Over 30% of Aclaris Therapeutics, Signaling Strong Confidence Amid 4% Stock Rally and Phase‑III Anticipation
Insider buying surges at Aclaris Therapeutics—directors pile on shares ahead of a Phase III launch, signaling confidence and potential upside for investors.
4 minutes to read


